Drug Profile
PF 06482077
Alternative Names: 20-valent Pneumococcal Conjugate Vaccine - Pfizer; 20vPnC; APEXXNAR; Multivalent Pneumococcal conjugate vaccine - Pfizer; PCV20; PCV20 - Pfizer; PF-06482077; Pneumococcal 20-valent Conjugate Vaccine; Pneumococcal conjugate vaccine - Pfizer; PREVENAR 20; PREVNAR 20Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pneumococcal infections
- Registered Otitis media
Most Recent Events
- 13 Mar 2024 Registered for Otitis media (In adolescents, In children, In infants, Prevention) in Liechtenstein, Iceland, Norway, European Union (IM)
- 13 Mar 2024 Registered for Pneumococcal infections (In adolescents, In children, In infants, Prevention) in European Union, Norway, Liechtenstein, Iceland (IM)
- 31 Jan 2024 Preregistration for Otitis media (In adolescents, In children, In infants, Prevention) in European Union (IM)